ARTH
Price
$0.23
Change
-$0.00 (-0.00%)
Updated
Dec 18 closing price
BETRF
Price
$0.07
Change
-$0.00 (-0.00%)
Updated
Dec 18 closing price
Ad is loading...

ARTH vs BETRF

Header iconARTH vs BETRF Comparison
Open Charts ARTH vs BETRFBanner chart's image
Arch Therapeutics
Price$0.23
Change-$0.00 (-0.00%)
Volume$4.38K
CapitalizationN/A
BETTERLIFE PHARMA
Price$0.07
Change-$0.00 (-0.00%)
Volume$49.7K
CapitalizationN/A
ARTH vs BETRF Comparison Chart
Loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BETRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTH vs. BETRF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTH is a StrongBuy and BETRF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ARTH: $0.23 vs. BETRF: $0.07)
Brand notoriety: ARTH and BETRF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTH: 41% vs. BETRF: 191%
Market capitalization -- ARTH: $1.02M vs. BETRF: $9.53M
ARTH [@Biotechnology] is valued at $1.02M. BETRF’s [@Biotechnology] market capitalization is $9.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTH’s FA Score shows that 0 FA rating(s) are green whileBETRF’s FA Score has 0 green FA rating(s).

  • ARTH’s FA Score: 0 green, 5 red.
  • BETRF’s FA Score: 0 green, 5 red.
According to our system of comparison, BETRF is a better buy in the long-term than ARTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTH’s TA Score shows that 4 TA indicator(s) are bullish while BETRF’s TA Score has 3 bullish TA indicator(s).

  • ARTH’s TA Score: 4 bullish, 3 bearish.
  • BETRF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARTH is a better buy in the short-term than BETRF.

Price Growth

ARTH (@Biotechnology) experienced а +9.52% price change this week, while BETRF (@Biotechnology) price change was -0.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

ARTH is expected to report earnings on Aug 30, 2023.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BETRF($9.53M) has a higher market cap than ARTH($1.02M). BETRF YTD gains are higher at: 50.125 vs. ARTH (-96.823). BETRF has higher annual earnings (EBITDA): -3.87M vs. ARTH (-8.68M). ARTH has higher revenues than BETRF: ARTH (148K) vs BETRF (0).
ARTHBETRFARTH / BETRF
Capitalization1.02M9.53M11%
EBITDA-8.68M-3.87M224%
Gain YTD-96.82350.125-193%
P/E RatioN/AN/A-
Revenue148K0-
Total Cash30KN/A-
Total Debt9.39MN/A-
FUNDAMENTALS RATINGS
ARTH vs BETRF: Fundamental Ratings
ARTH
BETRF
OUTLOOK RATING
1..100
18
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9746
P/E GROWTH RATING
1..100
10049
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARTH's Valuation (87) in the null industry is in the same range as BETRF (100). This means that ARTH’s stock grew similarly to BETRF’s over the last 12 months.

ARTH's Profit vs Risk Rating (100) in the null industry is in the same range as BETRF (100). This means that ARTH’s stock grew similarly to BETRF’s over the last 12 months.

ARTH's SMR Rating (100) in the null industry is in the same range as BETRF (100). This means that ARTH’s stock grew similarly to BETRF’s over the last 12 months.

BETRF's Price Growth Rating (46) in the null industry is somewhat better than the same rating for ARTH (97). This means that BETRF’s stock grew somewhat faster than ARTH’s over the last 12 months.

BETRF's P/E Growth Rating (49) in the null industry is somewhat better than the same rating for ARTH (100). This means that BETRF’s stock grew somewhat faster than ARTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTHBETRF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 9 days ago
76%
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 16 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BETRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDOGX13.230.01
+0.08%
Hennessy Total Return Investor
APDDX21.96-0.11
-0.50%
Artisan Global Discovery Advisor
CGRWX31.74-0.21
-0.66%
Invesco Comstock Select A
WFMDX48.98-0.45
-0.91%
Allspring Special Mid Cap Value Admin
MNDCX15.51-0.17
-1.08%
MFS New Discovery C

ARTH and

Correlation & Price change

A.I.dvisor tells us that ARTH and EDSA have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARTH and EDSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTH
1D Price
Change %
ARTH100%
+16.67%
EDSA - ARTH
21%
Poorly correlated
-1.58%
HRMY - ARTH
20%
Poorly correlated
+1.72%
BIVI - ARTH
13%
Poorly correlated
-1.97%
APLIF - ARTH
12%
Poorly correlated
N/A
BETRF - ARTH
5%
Poorly correlated
-10.11%
More

BETRF and

Correlation & Price change

A.I.dvisor tells us that BETRF and ATXI have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BETRF and ATXI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BETRF
1D Price
Change %
BETRF100%
-10.11%
ATXI - BETRF
21%
Poorly correlated
-4.60%
CLABF - BETRF
20%
Poorly correlated
+18.29%
AVCTF - BETRF
15%
Poorly correlated
N/A
ARTH - BETRF
5%
Poorly correlated
+16.67%
BSEM - BETRF
3%
Poorly correlated
-1.45%
More